PreHIPEOS: Image Quality of EOSedge for Radiographic Evaluation of Hip Implant

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Recruiting
CT.gov ID
NCT05615701
Collaborator
(none)
120
1
1
23.6
5.1

Study Details

Study Description

Brief Summary

EOSedge is a precise, low dose imaging system that delivers full body, high-quality images covering the full set of musculoskeletal and orthopedic exams.

The objective of the study is to evaluate the quality of the focused pelvis/hip X-ray images on EOSedge compared to those performed on DR (current practice) to perform a preoperative radiographic evaluation of hip implant, A sufficient image quality on focused X-ray images performed on EOSedge would allow (1) to avoid the passage on two different radiographic systems (saving time) (2) to reduce the patient's x-ray radiation dose

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: EOSedge imaging
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Image Quality of the EOSedge Radiographic System Versus a Standard Digital Radiographic (DR) System for Preoperative Assessment for Hip Replacement or Revision Surgery
Actual Study Start Date :
Nov 16, 2022
Anticipated Primary Completion Date :
Nov 3, 2024
Anticipated Study Completion Date :
Nov 3, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: EOSedge imaging

Single arm study : All subjects include in the study underwent micro-dose EOS x-ray and digital radiography for radiographic evaluation of hip implant

Diagnostic Test: EOSedge imaging
Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery

Outcome Measures

Primary Outcome Measures

  1. Score of Image quality [Day 0]

    Each criteria is quantitative and combined to obtain a final quantitative score : Perfect reproduction = 2 / Moderate reproduction = 1 / Poor or uninterpretable reproduction = 0 Artifacts ? = no or absence of periprosthetic material = 1; YES = 0 X-ray image acceptable ? = Fully acceptable = 2; Acceptable only under limited clinical conditions = 1; Unacceptable (indicate why) = 0; OUTOCOME = FINAL SCORE European C, Directorate-General for R, Innovation, Carmichael J, Moores B, Maccia C. Guide européen relatif aux critères de qualité des clichés de radiodiagnostic: Publications Office, 2000. Kogon PL, Lumsden R. How do you critique your radiographs? The Journal of the Canadian Chiropractic Association. 1993; 37(4):230-232. Cook JV, Kyriou JC, Pettet A, Fitzgerald MC, Shah K, Pablot SM. Key factors in the optimization of paediatric X-ray practice. The British journal of radiology. 2001; 74(887):1032-1040.

Secondary Outcome Measures

  1. Dosimetry [Day 0]

    The X-ray exposure dose induced by standard radiography and EOSedge will be compared. The radiation delivered to the patient during standard and EOSedge radiography will be quantified according to the dose × area product (DAP) [Gy.cm2] (dose * area product), for each exposure

  2. Dosimetry [Day 0]

    The X-ray exposure dose induced by standard radiography and EOSedge will be compared. The radiation delivered to the patient during standard and EOSedge radiography will be quantified according to the entry dose [mGy]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18 years of age or older

  • Came to the imaging department to perform a preoperative assessment for hip replacement or revision

Exclusion Criteria:
  • Patient under guardianship or curatorship

  • Patient participating in an interventional study

  • Patient unable to read and/or write

Contacts and Locations

Locations

Site City State Country Postal Code
1 Departement of Medical Imaging Montpellier Occitanie France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier

Investigators

  • Principal Investigator: Catherine c-cyteval@chu-montpellier.fr, MD, PhD, Departement of Medical Imaging - Montpellier University hospital LAPEYRONIE Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT05615701
Other Study ID Numbers:
  • RECHMPL22_0298
First Posted:
Nov 14, 2022
Last Update Posted:
Nov 25, 2022
Last Verified:
Nov 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 25, 2022